Thumbnail Image
Item

Brentuximab vedotin plus chemotherapy for the treatment of front-line systemic anaplastic large cell lymphoma: subgroup analysis of the ECHELON-2 study at 5 years' follow-up

Domingo-Domènech, E.
; 
Pro, B.
; 
Illidge, T.
; 
Horwitz, S.
; 
Trumper, L.
; 
Iyer, S.
; 
Advani, R.
; 
Bartlett, N. L.
; 
Christensen, J. H.
; 
Kim, W. S.
... show 10 more
Citations
Google Scholar:
Lookup
Altmetric:
Abstract
ClinicalTrials.gov number: NCT01777152.
Authors
Domingo-Domènech, E.
Pro, B.
Illidge, T.
Horwitz, S.
Trumper, L.
Iyer, S.
Advani, R.
Bartlett, N. L.
Christensen, J. H.
Kim, W. S.
Feldman, T.
Choi, I.
Gritti, G.
Belada, D.
Shustov, A.
Illes, A.
Zinzani, P. L.
Hüttmann, A.
Trneny, M.
Le Gouill, S.
Jagadeesh, D.
Friedberg, J. W.
Little, M.
Dong, C.
Fanale, M.
Fenton, K.
Savage, K. J.
Affiliation
Department of Hematology, Institut Catala D'Oncologia, Hospital Duran i Reynals; Institut de reserca IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain. edomingo@iconcologia.net. Division of Hematology and Oncology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA. Columbia University Irving Medical Center, New York, NY, USA. NIHR Biomedical Research Centre, Manchester Academic Health Sciences Centre, Christie Hospital NHS Foundation Trust, University of Manchester, Manchester, UK. Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Universitätsmedizin Göttingen, Göttingen, Germany. MD Anderson Cancer Center/University of Texas, Houston, TX, USA. Division of Oncology, Department of Medicine Division of Oncology, Stanford University, Stanford, CA, USA. Siteman Cancer Center, Washington University School of Medicine in St Louis, St. Louis, MO, USA. Odense University Hospital, Odense, Denmark. Division of Hematology-Oncology, Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. John Theurer Cancer Center, Hackensack Meridian Health, Hackensack, NJ, USA. Department of Hematology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan. Division of Hematology and Bone Marrow Transplant, ASST Papa Giovanni XXIII, Bergamo, Italy. 4th Department of Internal Medicine -Hematology, Charles University, Hospital and Faculty of Medicine, Hradec Králové, Czechia. University of Washington Seattle Cancer Care Alliance & Fred Hutchinson Cancer Research Center, Seattle, WA, USA. Cellectar Biosciences Inc., New Jersey, NJ, USA. Division of Hematology, Department of Internal Medicine, Faculty of Medicine, University of Debrecen, Debrecen, Hungary. IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia 'Seràgnoli', Bologna, Italy. Dipartimento di Scienze Mediche e Chirurgiche, Università di Bologna, Bologna, Italy. Universitatsklinikum Essen, Nordrhein-Westfalen, Germany. First Faculty of Medicine at Charles University Hospital, Prague, Czechia. Service d'hématologie, Institut Curie, Saint Cloud, France, Versailles, France. Laboratoire d'Imagerie Translationnelle en Oncologie (LITO), U1288 Inserm/Institut Curie Centre de Recherche, Paris, France. Université de Versailles Saint-Quentin (UVSQ), Versailles, France. Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA. Wilmot Cancer Institute, University of Rochester, Rochester, NY, USA. Takeda Development Center Americas, Inc. (TDCA), Cambridge, MA, USA. Cogent Biosciences, Waltham, MA, USA. Vertex Pharmaceuticals, Boston, MA, USA. Seagen Inc, Bothell, WA, USA. Centre for Lymphoid Cancer and Department of Medical Oncology, BC Cancer, Vancouver, BC, Canada.
Description
Date
2025
Publisher
Collections
All Christie Publications
Show all metadata
Files
Thumbnail Image
Found from Unpaywall
Adobe PDF, 572.76 KB
Keywords
Type
Article
Citation
Domingo-Domènech E, Pro B, Illidge T, Horwitz S, Trumper L, Iyer S, et al. Brentuximab vedotin plus chemotherapy for the treatment of front-line systemic anaplastic large cell lymphoma: subgroup analysis of the ECHELON-2 study at 5 years' follow-up. Blood Cancer J. 2025 Aug 1;15(1):129. PubMed PMID: 40750774. Pubmed Central PMCID: PMC12317119 BeiGene. TI: speakers fee: Takeda; consulting fees: Takeda. SH: honoraria: ADC Therapeutics, Affimed, Aileron, Celgene, Crispr Therapeutics, Daiichi Sankyo, Forty Seven, Inc., Kyowa Hakko Kirin, Millennium /Takeda, Seattle Genetics, Trillium Therapeutics, and Verastem/SecuraBio; consulting fees: Acrotech Biopharma, ADC Therapeutics, Astex, Auxilus Pharma, Merck, C4 Therapeutics, Celgene, Cimieo Therapeutics, Daiichi Sankyo, Janssen, Kura Oncology, Kyowa Hakko Kirin, Myeloid Therapeutics, ONO Pharmaceuticals, Seattle Genetics, SecuraBio, Shoreline Biosciences, Inc, Takeda, Trillium Therapeutics, Tubulis, Verastem/SecuraBio, Vividion Therapeutics, and Yingli Pharma Limited; grants or funds: NIH/NCI Cancer Center Support Grant P30 CA008748; a Specialized Center for Research grant from the Leukemia and Lymphoma Society (7026-21 [S.M.H.]); a Career Development Program Award from the Leukemia and Lymphoma Society (2332-20 [A.J.M.]), and Nonna’s Garden Foundation. SI: honoraria: Target Oncology, BioCure, ASTCT, ISLH; consulting fees: Seagen, Pfizer, Acrotech, DrenBio, and Yingli; grants or funds: Merck, Seagen, Innate, Legend, CRISPR, Acrotech, AstraZeneca, Myeloid, Ono, and DrenBio. RA: grants or funds: Institution Research Support. NLB: advisory council or committee: ADC Therapeutics; Foresight Diagnostics; Kite; Roche/Genentech; and Seattle Genetics; grants or funds: ADC Therapeutics; Autolus; Bristol Myers Squibb (BMS)/Celgene; Forty Seven; Gilead/Kite Pharma; Janssen; Merck; Millennium; Pharmacyclics; Roche/Genentech; and Seattle Genetics. WSK: consulting fees: Celltrion; grants or funds: Sanofi, Beigene, Donaga, Boryong, and Roche. TF: honoraria: Seagen, and Takeda; consulting fees: Seagen, and Takeda. GG: advisory council or committee: Takeda, Genmab, Roche, Kite-Gilead, Italfarmaco, and Ideogen; training activity: Clinigen, Incyte, Novartis, and Takeda; support for attending meetings: Sandoz, Beigene, and Janssen. DB: advisory council or committee: Takeda, Roche, Janssen-Cilag, Gilead Sciences, and Genmab; consulting fees: Takeda, and Roche. BP: honoraria: Takeda. AS: employment: Cellectar Biosciences; ownership of stock/shares: Cellectar Biosciences. AI: advisory council or committee: AbbVie, Janssen, Celgene, Novartis, Takeda, Pfizer, and Roche; consulting fees: AbbVie, Janssen, Celgene, Novartis, Takeda, Pfizer, and Roche. PLZ: honoraria: Takeda, Gilead, MSD, Novartis, Incyte, BeiGene, AbbVie, Roche, Kyowa Kirin, AstraZeneca, Janssen, and Regeneron; consulting fees: Takeda, Gilead, Merck Sharp & Dohme, Novartis, Incyte, BeiGene, AbbVie, Roche, Kyowa Kirin, AstraZeneca, Janssen, and Regeneron. MT: advisory council or committee: Takeda, BMS, Incyte, AbbVie, Amgen, Roche, Gilead Sciences, Janssen, MorphoSys, Novartis, Genmab, SOBI, Autolus, and Caribou Biosciences; honoraria: Janssen, Gilead Sciences, Takeda, BMS, Amgen, AbbVie, Roche, MorphoSys, and Novartis. ML: ownership of stock/shares: Takeda. CD: employment: Takeda; ownership of stocks/shares: Takeda, and Seagen. MF: employment: Seagen; ownership of stock/shares: Seagen. KF: employment: Seagen; ownership of stock/shares: Seagen KJS: advisory council or committee: BMS; honoraria: BMS, Seagen, and AbbVie; consulting fees: Seagen; grants or funds: BMS, and Roche (institutional); steering committee: DSMC: Regeneron. LT, JHC, IC, AH, SL, DJ, and JWF all have no potential conflict of interest to report. Epub 2025/08/02. eng.
Journal Title
Journal ISSN
Volume Title
URI
https://christie.openrepository.com/handle/10541/627559
Embedded videos